Search Share Prices
Oxford BioDynamics presents ALS biomarker data at CNS Summit
AIM-quoted biotechnology firm Oxford BioDynamics has presented its latest biomarker data in a plenary talk at the sixth World CNS Summit in Boston, Massachusetts after it identified non-invasive biomarkers for the diagnosis and prognosis of neurodegenerative and psychiatric disorders.
Oxford Bio demonstrated that EpiSwitch, its new biomarker, saw results in patients suffering from ALS, a progressive neurodegenerative disorder with no single diagnostic test, that defined "actionable stratifications for individual patients on the basis of high-resolution detection of chromosome conformations and regulatory genome 3D architecture."
Additional applications and examples of chromosome conformation stratifications were also presented and discussed at the CNS Summit for the extended range of indications of neurodegeneration, psychiatric disorders and related autoimmune and inflammatory conditions, including multiple sclerosis, lupus, treatment-resistant depression, autism and post-traumatic stress disorder.
Dr Alexandre Akoulitchev, chief scientific officer of Oxford BioDynamics, said, "We believe that delivering non-invasive prognostic biomarkers for ALS and building the insights into sub-typing of ALS is highly important. We aim to provide practical solutions that could benefit each and every individual patient that undergoes prognostic evaluation as early as possible and then receives one of the few available treatments."
"Earlier reports and the latest published validations of EpiSwitch stratifications from diagnostic, prognostic and biomarkers for response to treatment, gives OBD a unique opportunity to make a highly valuable contribution to improved patient care, clinical decisions and evidence of efficacy in drug treatments," he concluded.
As of 1000 GMT, shares had lost 1.21% to 163.00p.